BioSpace News Archive

bioAffinity Technologies today announced that Sandeep Bansal, M.D., Medical Director of Lung Innovations Network, has joined the Company’s Medical and Scientific Advisory Board.

SELLAS Life Sciences Group, Inc. today announced a publication in Oncotarget revealing the underlying mechanisms of action behind the anti-proliferative effects of SLS009 (formerly GFH009).

Nanalysis Scientific Corp., a leader in portable NMR machines, MRI technology for industrial and research applications, and detection equipment services, provides an estimate of Q4 2023 unaudited revenue and highlights some other recent business accomplishments.

Vistagen today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 third quarter ended December 31, 2023 and provide a corporate update.

BioMarin Pharmaceutical Inc. today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) today announced that it has received authorization from the Uzbekistan Ethics Committee to open the clinical trial site for its proof-of-concept human clinical study evaluating the use of transvascular ablation for the treatment of pancreatic cancer pain.

Complete Genomics, a California-based life sciences company that provides novel, comprehensive sequencing solutions, highlighted expanded sequencing applications enabled by DNBSEQ™-T7, a leading high- throughput sequencer which will be the subject of customer talks at the Advances in Genome Biology and Technology General Meeting.

Rancho Biosciences is pleased to announce its partnership with EMD Serono, Takeda and a top 10 pharma company as charter members of the groundbreaking Spatial Innovation Initiative.

Lineage Cell Therapeutics, Inc. today announced that it entered into a definitive agreement with certain investors for the purchase and sale of 13,461,540 of the company’s common shares in a registered direct offering at an offering price of $1.04 per common share.

For years there wasn’t an easy way. Then, in 2019, a team of chemists and bioinformatic experts from MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, debuted a new tool, known as the DOZN™ tool.